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Amiodarone-Induced Thyrotoxicosis and 
Ventricular Arrhythmias: Case Report and Review 
of the Literature
Ashish Shah, MD
INTRODUCTION
Amiodarone is a common drug used to treat arrhythmias 
and its side effects are diverse. An important adverse effect 
is amiodarone-induced thyrotoxicosis (AIT), which can 
potentially lead to a pro-arrythmogenic state. There have 
been limited studies on the pathogenesis of how thyrotox-
icosis increases the risk of ventricular arrhythmias, which 
causes providers to face a therapeutic challenge in patients 
who require this medication for the prevention of life 
threatening arrhythmias. This case report will present a 
patient with a left ventricular assist device (LVAD) who had 
recurrent ventricular arrhythmias on chronic amiodarone 
therapy in the setting of AIT.
CASE PRESENTATION
A 50 year old male with history of non-ischemic cardiomy-
opathy (EF 15%) and an LVAD awaiting transplant presented 
to the hospital in ventricular fibrillation/torsades de pointes 
requiring electrical cardioversion. His other past medical 
history included hypertension, obstructive sleep apnea, 
hyperlipidemia, chronic kidney disease and ventricular 
tachycardia status post implantable cardioverter defibrillator 
(ICD) placement. The patient’s ICD was removed a year 
prior to admission due to device endocarditis, MRSA/MSSA 
bacteremia, and epidural abscess/spinal osteodiscitis. Due 
to the history of ventricular tachyarrhythmias and removal 
of the ICD, he was on chronic amiodarone therapy (200mg 
per day) for the past 1.5 years. 
On admission he denied any symptoms of thyroid 
dysfunction such as weight changes, temperature 
sensitivity, recent fractures, fatigue/weakness, changes in 
bowel movements, hair loss, or changes in sleep. On 
physical exam, his vital signs were stable following 
cardioversion and he appeared clinically euthyroid without 
signs of thyroid associated ophthalmopathy (TAO), moist 
palms or dry skin, tremor, peripheral edema, or abnormal 
skin temperature. His thyroid exam was normal. Significant 
laboratory studies are shown in Table 1.   
DIFFERENTIAL DIAGNOSIS
Based on the laboratory values, the differential includes 
thyroid diseases  such as Graves’ Disease, thyroiditis, toxic 
nodule or toxic multinodular goiter or AIT type 1 or type 
2. The combination of radioactive iodine uptake (RAIU) 
and scan, the detection of autoantibodies, and color flow 
Doppler sonography can help narrow down this 
differential.
OUTCOME AND FOLLOW-UP
During the patient’s hospital stay, he was continued on an 
increased dose of amiodarone therapy and a new ICD 
was placed successfully without complications. A thyroid 
ultrasound revealed a hypoechoic right thyroid nodule 
measuring 1.6 x 0.9 x 1.1 cm and normal thyroid size. A 
radioactive thyroid uptake and scan showed markedly 
reduced thyroid activity. An ultrasound guided biopsy of 
the thyroid nodule showed minimal blood flow through 
the nodule using Doppler evaluation. The FNA was 
performed to rule out malignancy in the setting of being 
on the transplant list and the pathology was a benign 
follicular nodule. Thyroid Stimulating Immunoglobulins 
were not elevated. He was diagnosed as having type 2 
AIT. Upon discharge, the patient’s amiodarone dose was 
Table 1: Thyroid Function Studies 
 1 month 
after hospital 
admission
During  
hospital 
admission 
2 months 
prior to 
admission 
1 year prior to 
admission (6 months on 
amiodarone therapy)
2 years prior to 
admission (before 
amiodarone therapy)
Thyroid Stimulating 
Hormone (uIU/mL)  
(normal 0.3-5)
0.58 <0.02 <0.02 5.21 2.40
Free T4 (ng/dL) 
(normal 0.7-1.7)
1.3 1.9 3.6 1.5 Not checked
Free T3 (ng/dL) 
(normal 2-4.2)
1.9 3.8
Not 
checked
Not checked Not checked
ENDOCRINOLOGY
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increased to 400mg daily. The patient was followed as an 
outpatient and his thyroid function tests normalized 
within one month of hospitalization without requiring 
therapy. His thyroid function tests continue to be closely 
monitored and he is currently listed for heart transplant.
DISCUSSION
Amiodarone is an iodine rich drug that is used commonly 
in the treatment of both ventricular and atrial arrhythmias. 
Amiodarone affects multiple organ systems and can have 
varying effects on the thyroid as well. It can result in 
abnormalities in thyroid function tests as well as clinically 
apparent thyrotoxicosis or even hypothyroidism. 
Amiodarone is 37% iodine by weight and is structurally 
similar to T41. Taking 200mg of amiodarone daily releases 
approximately 7mg of iodide per day, which far exceeds 
the daily recommended optimal dose of iodine of 150ug1. 
Amiodarone and its metabolite, desethylamiodarone, 
have long half-lives of approximately 53 days and 61 days 
respectively1. As a result of the increased iodine content, 
a very long half life, and systemic distribution into the 
adipose tissues, amiodarone can continue to cause 
clinical effects after cessation of therapy. 
For patients who are on chronic amiodarone therapy and 
are clinically euthyroid, thyroid function tests typically 
display an increased serum T4 concentration and a 
decreased serum T3 concentration1. Amiodarone inhibits 
the type 1-5’-deiodinase in peripheral tissues, which is 
responsible for the conversion of T4 to T31. Typically, 
patients will have serum T4 concentrations at the upper 
limit of normal and serum T3 concentrations within the 
low normal range. The TSH in these patients are usually 
normal however initially after starting amiodarone therapy 
the TSH can be elevated as was seen in our patient after 
he was on therapy for 6 months1. 
AIT has an incidence of 14-18% of patients on chronic 
amiodarone therapy1. A significant risk factor for this 
adverse effect is taking a dose of 200mg daily1. 
Thyrotoxicosis can occur at any point during amiodarone 
therapy, with an average length of treatment being three 
years before occurrence1. AIT has been classified into two 
types (type 1 AIT and type 2 AIT), although distinguishing 
between both types can be difficult. 
In type 1 AIT, excessive thyroid hormone synthesis is 
induced by the iodine load associated with amiodarone 
therapy1. These patients typically have a prior thyroid 
abnormality such as diffuse or nodular goiter or latent 
Graves’ disease and live in a geographic area that is slightly 
iodine-deficient1. Their thyroid gland does not respond to 
the iodine load which would normally decrease the 
synthesis of thyroid hormone, but it rather continues to 
uptake more iodine and synthesize more thyroid hormone 
1. This type of AIT has increased RAIU and normal or 
slightly elevated serum interleukin 6 levels, a cytokine that 
indicates thyroid cell destruction, and thus there is no 
significant thyroid cell destruction in type 1 AIT1. On 
ultrasound with color flow Doppler, there is an increase in 
color flow indicating hypervascularity as well as increased 
functioning of the thyroid1.
Patients with type 2 AIT typically have a normal thyroid 
gland prior to amiodarone therapy and do not have 
thyroid autoantibodies1. They have very low RAIU and 
elevated serum interleukin 6 levels1. On ultrasound with 
color flow Doppler, there is typically less color flow in any 
area of the thyroid indicating decreased vascularity and 
decreased function of the thyroid gland1. These features 
of type 2 AIT infer that the pathophysiology involves 
thyroid cell destruction with evidence follicular damage1. 
The damaged follicles then release their preformed 
thyroid hormones leading to clinical symptoms of AIT. 
Table 2 summarizes the classification of AIT. 
Treatment of type I AIT is primarily blocking organification 
of excess iodine and the synthesis of thyroid hormones1. 
Higher doses of thionamides such as methimazole or 
propylthiouracil are utilized. Another drug used to block 
the excess iodine from entering the thyroid is potassium 
Table 2: Amiodarone-induced thyrotoxicosis classification1
Type 1 Type 2
Goiter/thyroid autoantibodies Present Absent
RAIU Low/normal/increased Low
Interleukin 6 serum level Normal/slight increase Elevated
Color flow Doppler ultrasound Increased color flow Decreased color flow
Response to thionamides Yes No
Response to perchlorate Yes No
Response to glucocorticoids No Yes
Subsequent hypothyroidism No Possible
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perchlorate (although not available in the US), which can 
be combined with the thionamides. Treatment of type 2 
AIT is primarily with high dose steroids (40-60mg/day) 
due to their anti-inflammatory and membrane stabilizing 
effects on the thyroid along with inhibition of 
5’-deiodinase1. If a patient has features of both type 1 and 
type 2 AIT, a combination of thionamides/potassium 
perchlorate and steroids can be used. If these treatment 
options are not successful, the last options are radioactive 
iodine (for type 1) or total thyroidectomy (for both). 
In our patient, his T4 was elevated in the setting of a 
suppressed TSH both two months prior to admission and 
on admission. He had a right thyroid nodule but no 
known autoantibodies or prior thyroid dysfunction. His 
RAIU was suppressed throughout the thyroid gland. 
Interleukin 6 levels were not obtained. On thyroid 
ultrasound, there was no increased color flow uptake. As 
a result, the patient was diagnosed with a likely mild case 
of type 2 AIT. Clinically, he had limited symptoms of 
thyrotoxicosis which may have been secondary to his 
previously prescribed beta-blocker (carvedilol). 
The more interesting finding is that this patient had an 
episode of ventricular fibrillation/torsades de pointes in 
the setting of type 2 AIT. A recent study done in Japan on 
patients on chronic amiodarone therapy showed that 
recurrent sustained ventricular tachycardia was significantly 
higher with thyrotoxicosis than in the euthyroid state4. 
Holter monitoring of these patients with thyrotoxicosis 
actually showed that the heart rate along with the number 
of ventricular premature complexes significantly 
increased4. One case report in Australia documented a 
patient on chronic amiodarone therapy for ventricular 
ectopy developing a coronary vasospasm and recurrent 
ventricular fibrillation in the setting of type 2 AIT5. It is 
difficult to conclude whether our patient’s type 2 AIT had 
any role in contributing to his ventricular fibrillation/
torsades de pointes episode prior to admission or whether 
this was the progression of his non-ischemic cardiomy-
opathy. It seems fair to conclude that triggers for his 
arrhythmia are multifactorial in nature. One recent study 
showed that the rate of major adverse cardiovascular 
events (cardiovascular mortality, myocardial infarction, 
stroke and heart failure, or ventricular arrhythmias requiring 
hospitalization) is 2.7 fold greater for those patients on 
long term amiodarone therapy who develop AIT than 
those who do not develop AIT, with ventricular arrhythmias 
being the most frequent type of event6. It has also been 
found that in the setting of AIT, severe left ventricular 
dysfunction is associated with increased mortality7. 
In conclusion, this case displays the effects of chronic 
amiodarone therapy on thyroid function. Clinicians must 
weigh the risks and benefits of using this anti-arrhythmic in 
the setting of a patient’s underlying cardiomyopathy. Given 
this patient’s history of ventricular arrhythmias, the benefit 
of being on amiodarone therapy greatly outweighs the risks 
of developing thyrotoxicosis. However after presenting to 
the hospital with episodes of ventricular fibrillation/torsades 
de pointes in the setting of type 2 AIT, one has to carefully 
follow the thyroid function tests to ensure biochemical 
normalization in order to minimize the risk for increased 
ventricular arrhythmia burden in addition to his worsening 
left ventricular ejection fraction. Overall, this is a unique 
case of an LVAD patient being bridged to transplant with 
recurrent ventricular arrhythmia on chronic amiodarone 
therapy who developed type 2 AIT. The management of 
these arrhythmias in the setting of AIT need to be further 
studied in order to balance the beneficial anti-arrhythmic 
properties of amiodarone with its harmful ability to cause 
thyrotoxicosis leading to a pro-arrythmogenic state. 
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